CompletedNCT00760747
Slow or fast switching from stimulants to atomoxetine for ADHD in children and teens
About this title
Read the official source — NCT00760747Researchers studied atomoxetine to find out how it affected ADHD symptoms in children with ADHD.
Medication studyAges 6–16Multiple countries
Understand this study
What did researchers investigate?
Researchers studied atomoxetine to find out how it affected ADHD symptoms in children with ADHD.
Who was this study for?
Listed age limits: 6 years to 16 years.
- Listed locations
- Milton and 5 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateSeptember 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 112
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Australia, United Kingdom, Mexico
- Age range
- From 6 Years to 16 Years
- Official registry ID
- NCT00760747
- Official title
Show the full official title
A Randomized, Controlled, Open-Label Comparison Study of the Efficacy and Safety of Slow Transitioning Compared With Fast Transitioning From a Stimulant Medication to Atomoxetine in Pediatric and Adolescent Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder (ADHD)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Milton, Australia · Zona Centro, Mexico · Fife, United Kingdom
3 more locations
- Sheffield, United Kingdom
- Birmingham, United Kingdom
- Northampton, United Kingdom
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers studied atomoxetine to find out how it affected ADHD symptoms in children with ADHD.
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine.
Who was this study for?
Listed age limits: 6 years to 16 years.
Want to explore more studies?
Explore studiesRelated studies
Atomoxetine or placebo to maintain response in adult ADHD
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) i...